GSE118056
scRNAseq reveals mechanisms of Merkel cell carcinoma acquired immunotherapy resistance [2]
PBMC and tumor specimen from a Merkel cell carcinoma tumor at time of immunotherapy resistance Overall design: PBMC and tumor specimen from a human patient with MCPyV associated Merkel cell carcinoma treated with T cell therapy and avelumab (anti-PD-L1), from a time point of late immunotherapy resistance; validation patient